Compugen Ltd. — FY 2015 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2015. This is an annual report, not a standalone fourth-quarter filing; quarterly results are not clearly provided in the filing text. Financial statements are audited and prepared under U.S. GAAP.
Business context and reporting period
Compugen is an Israeli therapeutic-discovery company whose business model centers on licensing and revenue-sharing collaborations for discovered drug targets and biologic candidates. Its early-stage pipeline focuses primarily on immuno-oncology and immune checkpoints, with additional antibody-drug conjugate and autoimmune-disease programs.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $9.277 million | $12.367 million |
| Gross profit / gross margin | $7.644 million / approximately 82% | $9.023 million / approximately 73% |
| Operating expenses | $28.562 million | $21.360 million |
| Operating loss | $20.918 million | $12.337 million |
| Net loss | $20.163 million; $0.40 per share | $11.094 million; $0.23 per share |
| Operating cash flow | $(25.607) million | $(11.148) million |
| Cash, short-term deposits and restricted cash at year-end | $81.421 million | $73.328 million |
| Total assets / shareholders’ equity | $99.307 million / $89.897 million | $114.986 million / $106.116 million |
Cash and cash equivalents alone were $10.777 million; short-term bank deposits were $69.567 million and restricted cash was $1.077 million. Current liabilities were $6.854 million. The filing reports no conventional debt balance; it does disclose $8.870 million of contingent OCS royalty obligations, payable if relevant products generate revenue. Year-end trade receivables were $7.800 million, principally associated with the Bayer milestone recognized in 2015.
Material changes versus the prior comparable period
- Revenue declined approximately 25%, while gross margin improved, mainly because cost of revenues fell 51% as Bayer collaboration expenses decreased.
- Research and development expense rose 40% to $21.245 million, reflecting expanded pipeline work, U.S. research and preclinical activity, and higher staffing. Total operating expenses increased 34%.
- Net loss widened by approximately $9.1 million, and operating cash use more than doubled. Cash and cash equivalents fell by $14.866 million; total cash, deposits and restricted cash nevertheless increased from 2014.
- Capital expenditures were $4.4 million, primarily for new Holon facilities and laboratory and computer equipment. Cash purchases of property and equipment were $3.120 million; $1.321 million remained unpaid at year-end.
Outlook, management commentary, risks and unusual items
- Management expects continued losses and stated R&D would remain more than 70% of operating expenses; the 2016 R&D budget was expected to rise by more than 20%. No revenue or profit guidance was provided.
- Management estimated available funds would support operations for at least 24–30 months in one section and 24–36 months in another. The filing therefore gives differing runway estimates.
- The Bayer collaboration is a major revenue source: one customer accounted for 99% of 2015 revenue. Compugen recognized a $7.8 million preclinical milestone in 2015; the amount was receivable at year-end. The agreement includes over $500 million in potential milestones across two programs, up to $30 million in preclinical milestones, and mid- to high-single-digit royalties on approved-product sales. These amounts are contingent, not assured revenue.
- Compugen selected CGEN-15029 as its highest-priority monoclonal-antibody program for advancement toward clinical testing. CGEN-15027 showed potent in-vitro cancer-cell killing in an ADC test. The programs remain early stage; clinical success and partnering are uncertain.
- Principal risks include dependence on collaborators and a single major customer, early-stage discovery and development failure, financing needs, competition, patent and freedom-to-operate challenges, foreign-exchange exposure, Israeli geopolitical conditions, and restrictions attached to Israeli government R&D grants.
- Management and the active chairman were deemed eligible for 2015 cash bonuses but waived them. The independent auditor gave an unqualified opinion on the financial statements and internal controls; management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Confirm the status and collection of the $7.8 million Bayer milestone receivable and the timing and conditions for future collaboration payments.
- Reconcile the stated cash runway estimates of 24–30 months and 24–36 months against projected spending and planned 2016 R&D growth.
- Review the full cash-flow statement and liquidity composition, including restricted balances, deposits, and the cash required to sustain planned pipeline investment.
- Track Bayer program progress, CGEN-15029 advancement toward an IND, and evidence supporting CGEN-15027 and other candidates; none of the filing’s potential milestone or sales amounts is guaranteed.
- Assess customer concentration, contingent OCS royalties and know-how restrictions, and potential dilution or financing needs.